Previous 10 | Next 10 |
2023-03-15 10:42:34 ET Clinical-stage pharma Cognition Therapeutics ( NASDAQ: CGTX ) announced Wednesday that the FDA cleared its Investigational New Drug (IND) application for the oral eye disease candidate CT1812. The IND was aimed at studying CT1812 for geographic atrop...
PURCHASE, N.Y., March 07, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced today that the Company’s president and CEO, Lisa Ricciardi will present at the annual Oppenheimer & Co Healthcare Con...
Nano-cap biotech Cognition Therapeutics ( NASDAQ: CGTX ) added ~13% pre-market Wednesday after announcing that the company is set to start its Phase 2 study for lead candidate CT1812 in adults with mild cognitive impairment or early Alzheimer's disease. The 540-patient trial named...
NEW YORK, Feb. 22, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that it has cleared the U.S. Food and Drug Administration comment period and may now proceed with the 540-patient Phase 2 START study of CT1812 in adults with mild cognitive impairment or ear...
PURCHASE, N.Y., Feb. 21, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (Nasdaq: CGTX), (the “Company” or “Cognition”) has released its third “Conversations” video podcast, featuring a discussion with two Lewy body dementia caregivers, who ar...
NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs that treat neurodegenerative disorders by regulating cellular damage response pathways, today announced that enrollment has comp...
- Features Alzheimer’s Experts: Christopher van Dyck, M.D. and Anton Porsteinsson, M.D. - PURCHASE, N.Y., Dec. 22, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. , (Nasdaq: CGTX), (the “Company” or “Cognition”) has released the second “...
PURCHASE, N.Y., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX) (the “Company” or “Cognition”), announced that the Phase 2 SHINE clinical trial of CT1812, an experimental oral, once-daily capsule in development for mild-to-moderate Alzheim...
PURCHASE, N.Y., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”) today announced that the scientific rationale, supporting proof-of-concept data and design of the planned Phase 2 trial of CT1812 in geogr...
PURCHASE, N.Y., Nov. 28, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (Nasdaq: CGTX), (the “Company” or “Cognition”), today announced that the rationale and design of the Company’s ongoing SHIMMER clinical trial of CT1812 will be presented at...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
13.5%Change Percent:
Cognition Therapeutics Inc. Company Name:
CGTX Stock Symbol:
NASDAQ Market:
Cognition Therapeutics Inc. Website:
2024-07-29 17:15:02 ET Cantor Fitzgerald analyst issues NEUTRAL recommendation for CGTX on July 29, 2024 04:08PM ET. CGTX was trading at $1.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 3 - Buy recom...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 1.3% to $111.59 on volume of 240,827,673 shares Lipella Pharmaceuticals Inc. (LIPO) rose 122.5% to $0.8992 on volume of 193,926,302 shares PROSHARES TRUST (SQQQ) fell 0.5% to $9.05 on volume of 150,372,371...
- CT1812 Treatment Showed ~40% Mean Improvement in Cognitive Measures vs Placebo - - Consistent Positive Changes Across Cognitive and Functional Measures - - Favorable Safety Profile with Most Treatment-Related Adverse Events Mild or Moderate - - Significant Changes in Neurofila...